First line chemotherapy with paclitaxel (P) and mitoxantrone (M) metastatic breast cancer (MBC). A phase II study

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

Objectives: The aim of this study was to evaluate the feasibility, efficacy and toxicity of Paclitaxel (P) and Mitoxantrone (M) combination as first line chemotherapy in patients with Metastatic Breast Cancer. Patients and Treatment: Between April 1997 and October 1998 fifty (50) patients (mean age 63 yrs, range 31-76 yrs) with Metastatic Breast Cancer were enrolled in this study. Twenty three (23) patients had received adjuvant combination chemotherapy, fourteen (14) CMF and nine (9) FEC. sixteen (16) patients had received adjuvant radiotherapy and twenty nine (29) hormonal therapy. All patients were treated on an outpatient basis with Paclitaxel (P) 175 mg!m’ in 3 hours infusion and Mitoxantrone (M) 12 mg/m2 in 30 minutes infusion i.v every 3 weeks for 6 courses. Patients were premeditated with standard antiemetic and antiallergig regimens. All patients received GCSF for 5 days.

Results: All patients were evaluable for toxicity and response. Grade 3-4 toxicity included neutropenia (12 pts), thromboytopenia (1 pt), peripheral neuropathy (7 pts) and cardiac toxicity (5 pts). Febrile neutropenia occurred in 2 pts. Grade 3 alopecia was observed in all patients. The ojective response rate was 4.4% (16% Complete response and 28% Partial response). The mean survival was 18. 36 * 1.06 months (Cl. 16, 29-20, 43).

Conclusions: Combination chemotherapy with Paclitaxel and Mitoxantrone is feasible, well tolerated and higly effective as first line treatment in patients with Metastatic Breast cancer.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

European Journal of Cancer

DOI

https://doi.org/10.1016/S0959-8049(99)81723-7

Link to Full Text

Share

COinS